Skip to main content

Advertisement

SpringerLink
Log in

Should newly diagnosed epilepsy be treated with generics?

  • Viewpoint
  • Published:

From Nature Clinical Practice Neurology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bialer M (2007) Generic products of antiepileptic drugs (AEDs): is it an issue? Epilepsia 48: 1825–1832

    Article  Google Scholar 

  2. Brodie MJ (2005) Response to antiepileptic drug therapy: winners and losers. Epilepsia 46 (Suppl 10): S31–S32

    Google Scholar 

  3. Kutt H (1972) Relation of plasma levels to clinical control. In Antiepileptic Drugs, 211–218 (Eds Woodbury DM et al.) New York: Raven Press

    Google Scholar 

  4. Søndergaard Khinchi M et al. (2008) Lamotrigine therapeutic thresholds. Seizure [10.1016/j.seizure.2007.11.023]

  5. Mayer T et al. (1999) Clinical problems with generic antiepileptic drugs: comparison of sustained-release formulations of carbamazepine. Clin Drug Invest 18: 17–26

    Article  CAS  Google Scholar 

  6. Perucca E et al. (2006) Recommendations of the Italian League Against Epilepsy working group on generic products of antiepileptic drugs. Epilepsia 47 (Suppl 5): S16–S20

    Article  Google Scholar 

  7. Wolf P (2007) Generic antiepileptic drugs: political campaign in Denmark. Epilepsia 48 (Suppl 7): S6–S7

    Google Scholar 

Download references

Author information

Author notes

  1. Danish Epilepsy Centre, Kolonivej 1, Dianalund, DK-4293, Denmark peterw@vestamt.dk

Authors and Affiliations

  1. P Wolf is Professor of Neurology/Epileptology at Copenhagen University Hospital, Copenhagen and at the Danish Epilepsy Centre, Dianalund, Denmark.,

    Peter Wolf

Authors
  1. Peter Wolf
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author has served as an advisor for Eisai, GlaxoSmithKline and UCB, and has been a speaker at conferences sponsored by these companies.

Supplementary information

Supplementary Figure 1

Drug plasma levels during dose titration with carbamazepine while switching between different drug preparations — a model case. (DOC 103 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wolf, P. Should newly diagnosed epilepsy be treated with generics?. Nat Rev Neurol 4, 176–177 (2008). https://doi.org/10.1038/ncpneuro0753

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneuro0753

  • Springer Nature Limited

This article is cited by

Search

Navigation